Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. - Wikidata - wikimedia - TriplyDB

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.

http://www.wikidata.org/entity/Q48238648

about

A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models Ligand exchange between proteins. Exchange of biotin and biotin derivatives between avidin and streptavidin Antibody-targeted radiation cancer therapy Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.In vivo assembly of nanoparticle components to improve targeted cancer imaging.Facile method for the site-specific, covalent attachment of full-length IgG onto nanoparticles Pretargeted radioimmunotherapy for hematologic and other malignancies Experimental approaches for the treatment of malignant gliomas.Cancer radioimmunotherapy.Single reporter for targeted multimodal in vivo imaging Monoclonal antibodies for brain tumour treatment.Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies.Targeted cancer therapy using radiolabeled monoclonal antibodies.Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases.Advances in radioimmunotherapy in the age of molecular engineering and pretargeting.Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.Radioimmunotherapy of brain tumor.Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study Emerging monoclonal antibody therapies for malignant gliomas.Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.Use of antibodies and immunoconjugates for the therapy of more accessible cancers.Immunotherapeutic approaches for glioma A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF.A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.Avidin-biotin technology in targeted therapy.Radioimmunotherapy: a brief overview.Streptavidin-biotin technology: improvements and innovations in chemical and biological applications.Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT).Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin.Engineering of a Bacillus subtilis strain with adjustable levels of intracellular biotin for secretory production of functional streptavidin.Escort aptamers: a delivery service for diagnosis and therapy.Characterization of poultry egg-white avidins and their potential as a tool in pretargeting cancer treatment.Cloning and characterization of Scavidin, a fusion protein for the targeted delivery of biotinylated molecules.Targeting of biotinylated compounds to its target tissue using a low-density lipoprotein receptor-avidin fusion protein.Novel avidin-like protein from a root nodule symbiotic bacterium, Bradyrhizobium japonicum.Efficient gene therapy based targeting system for the treatment of inoperable tumors.

P2860

Q24618342-5F4E506E-B35F-40B9-BA0C-BBEB8487D60B Q27311386-A5719C15-EEDA-4CA6-98A5-41FD8FD91EA3 Q27639140-6744D32B-540A-4DFC-BD0F-C881944DDD51 Q28264580-090FBD02-5CB0-4E71-BB08-5456FEF9E951 Q30480832-7393BE6B-C84B-482B-9868-603117B2AF22 Q33952969-F0CEAE64-42FC-404D-AFCE-EC6091EFF282 Q34079536-97298516-B2DA-48EB-BFB0-A25799F00705 Q34113941-2EF57EBA-A44F-47E3-9CE0-391CE036816B Q34127138-47AEF22A-314D-44A5-803A-EB82E73FC3FB Q35070045-018F73E6-29EA-4D90-BE9C-27F597472F5F Q35848195-4413FA2E-9E5E-4BB7-9F7A-39A55BB605D8 Q35873775-A15F20A5-B350-4D74-BCD5-6ECA8F66DC4C Q36200153-1FFB95E3-2598-4FB4-A6D8-0567ECC6A216 Q36200161-3279401E-2A6F-4513-A51B-7AB0CD8243DB Q36316942-24D8330D-6898-47B0-A250-7C1711FCEB5E Q36391426-A2427AE8-2531-4E28-822D-2E15F6BFED29 Q36395999-6EFE914E-A2E6-4C95-9997-9231CA182B61 Q36445890-88333B63-20B5-4B8C-9D5A-AE0C0860415A Q36523369-1C788798-584D-4459-9FD2-A057DE7574B1 Q36643720-605F13A2-F093-424E-A8E6-8415672E90B3 Q36764016-8376860E-452C-4C4B-BBB8-A5E7EFDDEF6B Q37079854-3DA24AC2-5C4B-4D3E-93B2-B4B396A90B1F Q37174938-F085FFC4-A78C-48AB-B84F-DB93FC9CED4E Q37267793-40487B54-6B35-4B17-9497-49897AFB181B Q37311057-F5FBC525-7AF7-4140-A9F6-969D4BDAD702 Q37675882-4A4A1C66-6DDC-477D-B1EA-FEFD022CFC2B Q37710089-28C27242-0F0B-4BCE-ADEC-5A174EDE2159 Q37879933-481D764C-AEE4-42A4-BB6C-230095C5DBD2 Q38140695-1BC98B14-E718-411A-BCB8-A2CD1CA20DA5 Q38294018-94B77ECC-98B8-44F2-95C0-1CA35FD745EF Q38726647-802A2962-2942-48F6-907D-D61E7B474BC2 Q38799356-5830FAB8-F1D6-4A0B-83D9-F6BFC7E84BA1 Q39572340-48D2A711-9068-46E0-92AC-3C25905F718D Q39639256-FE6D5C50-6F32-4DEE-8767-C96509D371ED Q40432036-2200B1B0-9875-452E-8554-4EE3D81A5999 Q43002836-4E3487EF-2724-4C4A-A934-8BFF96B9147F Q43821751-CB17C1AE-8EA5-411A-AA52-F3DEA09FAFA3 Q44640632-7AE04ACF-CB43-4CBF-96E8-8600449D440D Q45254066-C30BB94B-F5E8-41CF-97DC-E438F72A5E8F Q45877862-B179C0EE-4F57-4DD5-A4BE-8983C6E551AD

P2860

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.

http://www.wikidata.org/entity/Q48238648

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

1999年學術文章

@zh-hant

name

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.

@en

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.

@nl

type

label

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.

@en

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.

@nl

prefLabel

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.

@en

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.

@nl

P1433

Q48238648-87E879D9-E959-4D23-BA78-03DEC019E4A4

P1476

Q48238648-6F4F39BC-2B6A-4CEB-860F-48F8AEC28AF1

P2093

Q48238648-36A35F30-3097-405F-84A5-4ED2C8DA5D0C

Q48238648-48F9B4AB-CCA1-43B9-BCC6-B22182EBFC3B

Q48238648-4F3D4976-31BA-4AEC-9AA1-6894F2C991A5

Q48238648-7A1D36A9-4A8E-4A26-A15C-6EEEBF318B32

Q48238648-B2C1F33D-CD24-4DA2-8DD6-2D49F472D03C

Q48238648-BCADAE35-A3BA-4ED0-B4D2-5A251F917FD7

Q48238648-C41304A8-BE14-4128-8857-8F52F2F10183

Q48238648-E75502D7-C763-4294-B8F2-298161E863A7

Q48238648-E8AF788C-C628-4386-A37A-40969DE61CC5

Q48238648-FF68C62F-7E72-468C-8FAA-077F0A1D024C

P2888

Q48238648-8CCB1110-41B6-4131-9E76-8E90365F6ED0

P304

Q48238648-E587E916-B3D7-4562-AA8C-8A8DA56A94C7

P31

Q48238648-68488D8A-418C-437F-B19F-5C4301B23A07

P356

Q48238648-B6048B83-5965-4C4A-9958-60A530A0CA07

P433

Q48238648-EA7BEB8E-E50B-4DC1-9D98-969708C99D61

P478

Q48238648-9B15D765-F03C-49AC-9CA2-0BA37D4212B3

P50

Q48238648-94733953-FB3F-4F98-B05D-68839DA6CE1D

Q48238648-C90D347E-0CC4-4E9F-A5E9-1FA971278E2D

P577

Q48238648-14A1B310-3473-4BDA-BB78-18600B19990B

P698

Q48238648-F3A3F0B2-E16F-4C56-BB90-7A40A92A029E

P921

Q48238648-A8E1BC36-5628-4FFB-8BB2-1F7990CF4F10

P356

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.

@en

P2093

Casadio C

http://www.w3.org/2001/XMLSchema#string

Chinol M

http://www.w3.org/2001/XMLSchema#string

Cremonesi M

http://www.w3.org/2001/XMLSchema#string

De Cicco C

http://www.w3.org/2001/XMLSchema#string

Grana C

http://www.w3.org/2001/XMLSchema#string

Robertson C

http://www.w3.org/2001/XMLSchema#string

Siccardi AG

http://www.w3.org/2001/XMLSchema#string

Veronesi U

http://www.w3.org/2001/XMLSchema#string

Zoboli S

http://www.w3.org/2001/XMLSchema#string

Zurrida S

http://www.w3.org/2001/XMLSchema#string

P2888

P304

348-357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S002590050397

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Filippo de Braud

Giovanni Paganelli

P577

1999-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10199940

http://www.w3.org/2001/XMLSchema#string

P921